<style> .wpb_animate_when_almost_visible { opacity: 1; }</style>

Investors

HLS Therapeutics is a specialty pharmaceutical company focused on the acquisition and commercialization of late-stage development, commercial-stage promoted and established branded pharmaceutical products in the North American markets. We focus on products targeting the central nervous system and cardiovascular therapeutic areas. Our management team is comprised of seasoned pharmaceutical executives with a strong track record of success in these therapeutic areas and at managing products in each of these lifecycle stages. HLS Therapeutics listed publicly on the TSXV in March 2018 by way of a reverse takeover of Automodular Corporation.

EVENTS
Thursday, September 6, 2018


View All

SHARE PRICE
CDXHLS
INVESTOR PRESENTATION

The information contained on the Investor Relations section of this website was accurate at the time of posting, but may be superseded by subsequent disclosures. Please check the date of the material posted.


PRESS RELEASES
Sep 24, 2018

REDUCE-IT is First Outcomes Study to Assess Treatment of Patients with LDL-C Controlled by Statin Therapy, Persistent Elevated Triglycerides and Other Cardiovascular Risk Factors Results Specific...

Sep 6, 2018

HLS Therapeutics Inc. ("HLS" or the "Company") (TSX-V: HLS), a specialty pharmaceutical company specializing in central nervous system ("CNS") and cardiovascular markets, announces that it has...

Aug 22, 2018

HLS Therapeutics Inc. ("HLS" or the "Company") (TSX-V: HLS), a specialty pharmaceutical company specializing in central nervous system ("CNS") and cardiovascular markets, announces that it has...


Read More